MX2024009163A - Sintesis de un inhibidor de kif18a. - Google Patents

Sintesis de un inhibidor de kif18a.

Info

Publication number
MX2024009163A
MX2024009163A MX2024009163A MX2024009163A MX2024009163A MX 2024009163 A MX2024009163 A MX 2024009163A MX 2024009163 A MX2024009163 A MX 2024009163A MX 2024009163 A MX2024009163 A MX 2024009163A MX 2024009163 A MX2024009163 A MX 2024009163A
Authority
MX
Mexico
Prior art keywords
compound
kif18a
inhibitor
synthesis
salt
Prior art date
Application number
MX2024009163A
Other languages
English (en)
Spanish (es)
Inventor
Sebastien Caille
Daniel Gerard Greene
Michael Thomas Corbett
Carolyn Wei
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2024009163A publication Critical patent/MX2024009163A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C313/00—Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C313/02—Sulfinic acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
MX2024009163A 2022-01-26 2023-01-26 Sintesis de un inhibidor de kif18a. MX2024009163A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263303470P 2022-01-26 2022-01-26
PCT/US2023/011636 WO2023146973A1 (en) 2022-01-26 2023-01-26 Synthesis of a kif18a inhibitor

Publications (1)

Publication Number Publication Date
MX2024009163A true MX2024009163A (es) 2024-08-09

Family

ID=85328813

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024009163A MX2024009163A (es) 2022-01-26 2023-01-26 Sintesis de un inhibidor de kif18a.

Country Status (12)

Country Link
US (1) US20250129050A1 (cg-RX-API-DMAC10.html)
EP (1) EP4469437A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025505892A (cg-RX-API-DMAC10.html)
KR (1) KR20240144140A (cg-RX-API-DMAC10.html)
CN (1) CN118922406A (cg-RX-API-DMAC10.html)
AR (1) AR128353A1 (cg-RX-API-DMAC10.html)
AU (1) AU2023211589A1 (cg-RX-API-DMAC10.html)
CA (1) CA3248925A1 (cg-RX-API-DMAC10.html)
IL (1) IL314221A (cg-RX-API-DMAC10.html)
MX (1) MX2024009163A (cg-RX-API-DMAC10.html)
TW (1) TW202342451A (cg-RX-API-DMAC10.html)
WO (1) WO2023146973A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL283639B2 (en) 2018-12-20 2024-06-01 Amgen Inc Kif18a inhibitors
CR20250087A (es) 2022-08-18 2025-07-11 Accent Therapeutics Inc Inhibidores de kif18a y usos de estos
CN115925589A (zh) * 2022-12-26 2023-04-07 诚达药业股份有限公司 一种脂肪族亚磺酸钙盐及其制备方法
CN121693499A (zh) * 2023-08-16 2026-03-17 上海湃隆生物科技有限公司 驱动蛋白kif18a抑制剂及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL283639B2 (en) * 2018-12-20 2024-06-01 Amgen Inc Kif18a inhibitors
JP2023521802A (ja) * 2020-04-14 2023-05-25 アムジエン・インコーポレーテツド 新生物疾患の処置のためのkif18a阻害剤

Also Published As

Publication number Publication date
CA3248925A1 (en) 2023-08-03
AR128353A1 (es) 2024-04-24
WO2023146973A1 (en) 2023-08-03
AU2023211589A1 (en) 2024-07-25
US20250129050A1 (en) 2025-04-24
KR20240144140A (ko) 2024-10-02
TW202342451A (zh) 2023-11-01
IL314221A (en) 2024-09-01
EP4469437A1 (en) 2024-12-04
JP2025505892A (ja) 2025-03-03
CN118922406A (zh) 2024-11-08

Similar Documents

Publication Publication Date Title
AR128353A1 (es) Síntesis de un inhibidor de kif18a
AR117101A1 (es) Síntesis mejorada del intermedio clave del compuesto inhibidor de g12c de kras
CO2023014807A2 (es) Compuesto cíclico que contiene acción inhibidora selectiva en kras por sobre hras y nras
MX2022010795A (es) Hidrato cristalino de un compuesto inhibidor de jak.
PE20231938A1 (es) Inhibidores de cdk y metodos de uso de estos
CL2024003354A1 (es) Compuesto cíclico que tiene acción inhibitoria selectiva sobre kras por encima de hras y nras
CL2021000737A1 (es) Fabricación de compuestos y composiciones para inhibir la actividad de shp2
CO2024001367A2 (es) Compuestos antivirales
CO6400227A2 (es) Análogos de nucleosidos
CL2020001871A1 (es) Dihidrobenzofurano e inden analogos como inhibidores de sarcómero cardíaco.
PE20050012A1 (es) Compuestos de benzopirano como inhibidores de la ciclooxigenasa-2
MX2024012348A (es) Forma cristalina de lanifibranor
DOP2025000087A (es) Compuestos tricíclicos y sus usos
CY1111481T1 (el) Υποκατεστημενα αρυλοκυκλοπροπυλακεταμιδια ως ενεργοποιητες γλυκοκινασης
AR069798A1 (es) Derivados de 1, 3-tiazol, metodos para su preparacion, composiciones farmaceuticas que los comprenden y su uso en la manufactura de medicamentos para el tratamiento de enfermedades mediadas por la fosfatidilinositol 3-cinasa.
CY1114689T1 (el) C7-φθορο υποκατεστημενες ενωσεις τετρακυκλινης
MXPA04002993A (es) Compuestos de espiro-hidantoina utiles como agentes anti-inflamatorios.
AR124694A1 (es) Hidrato cristalino de sal de sodio de topramezona novedoso y método de preparación del mismo
CO2024013702A2 (es) Derivados de pirido-[3,4-d]piridazina amina útiles como derivados de nlrp3
CL2021002575A1 (es) Compuestos de pirrol
EA201290872A1 (ru) Способ получения бензоксаборолов
UY39898A (es) Un proceso para la preparación de piroxasulfona.
CL2021000171A1 (es) Procedimiento y productos intermedios para la preparación de bilastina
UY39789A (es) Intermedio novedoso para la preparación de piroxasulfona.
PE20191103A1 (es) Inhibidores de dopamina-b-hidroxilasa